Vertex Pharmaceuticals (VRTX) Total Debt (2009 - 2016)

Vertex Pharmaceuticals' Total Debt history runs 6 years deep, the most recent figure standing at $300.0 million for Q4 2016.

• In Q4 2016, Total Debt rose 1.64% year-over-year to $300.0 million; the TTM figure through Dec 2016 stood at $300.0 million (up 1.64% YoY), while the FY2016 annual figure was $300.0 million, up 1.64% from the prior year.
• Total Debt was $300.0 million for Q4 2016 at Vertex Pharmaceuticals, up from $297.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $300.0 million in Q4 2016 to a low of $294.7 million in Q3 2014.
• Historically, Total Debt has averaged $295.9 million across 3 years, with a median of $295.0 million in 2015.
• The sharpest annual moves came in 2015 and 2016: Total Debt grew 0.03% in 2015, then rose 1.64% in 2016.
• A 3-year view of Total Debt shows it stood at $294.8 million in 2014, then increased by 0.13% to $295.2 million in 2015, then gained by 1.64% to $300.0 million in 2016.
• The last three Total Debt figures came in at $300.0 million (Q4 2016), $297.8 million (Q3 2016), and $296.5 million (Q2 2016), per Business Quant data.